PREMM stands for PREdiction Model for gene Mutations. The PREMM prediction model is rigorously tested, widely recognized, and recommended by several professional societies, including the National Comprehensive Cancer Network, the American College of Gastroenterology, and the U.S. Multi-Society Task Force on Colorectal Cancer.
PREMMplus Model
PREMMplus is a clinical prediction algorithm that identifies individuals that should be considered for hereditary cancer risk assessment using multigene panel testing. PREMMplus evaluates an individual’s personal family history of cancer and related conditions for carrying a germline mutation in one of these cancer susceptibility genes: APC, ATM, BRCA1, BRCA2, BRIP1, CDKN2A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, biallelic MUTYH, PALB2, PMS2, PTEN, RAD51C, RAD51D, and TP53.
The PREMMplus model asks about the following cancers and related conditions:
The PREMMplus model was introduced in 2022 and identifies individuals that should be considered for hereditary cancer risk assessment using multigene panel testing. Details of model development are available in this publication: